SCHEMBL657511

SCHEMBL657511

O=C(/C=C/c1ccc2ccccc2c1)c1ccc(Cl)cc1

nearest known ligand 0.77

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.74
PTPN1 P18031 2/20 0.74
MAOB P27338 6/20 0.67
MAOA P21397 4/20 0.67
CYP1B1 Q16678 3/20 0.67
CXCL12 P48061 2/20 0.64
CYP1A2 P05177 2/20 0.62
MEN1 O00255 1/20 0.62
NPC1 O15118 1/20 0.62
CYP2C19 P33261 1/20 0.62
RAB9A P51151 1/20 0.62
KMT2A Q03164 1/20 0.62
CYP1A1 P04798 1/20 0.60
CYP2D6 P10635 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657512 1.00 CYP3A4 (0.74) CYP3A4PTPN1MAOBMAOACYP1B1
Bromide SCHEMBL11816272 0.98 CYP3A4 (0.72) CYP3A4PTPN1MAOBMAOACYP1B1
Bromide SCHEMBL11816270 0.98 CYP3A4 (0.72) CYP3A4PTPN1MAOBMAOACYP1B1
SCHEMBL11819929 0.91 CYP1B1 (0.77) CYP3A4PTPN1MAOBMAOACYP1B1
Bromide SCHEMBL11821954 0.90 CYP1B1 (0.75) CYP3A4PTPN1MAOBMAOACYP1B1
SCHEMBL656219 0.87 CYP3A4 (0.77) CYP3A4PTPN1MAOBMAOACYP1B1
SCHEMBL29624424 0.87 CYP3A4 (0.77) CYP3A4PTPN1MAOBMAOACYP1B1
SCHEMBL656427 0.87 CYP1B1 (0.81) CYP3A4PTPN1MAOBMAOACYP1B1
SCHEMBL656428 0.87 CYP1B1 (0.81) CYP3A4PTPN1MAOBMAOACYP1B1
SCHEMBL656220 0.87 CYP3A4 (0.77) CYP3A4PTPN1MAOBMAOACYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017029684-A1 2,3,5 TRISUBSTITUTED PYRROLE DERIVATIVES AS TOPOISOMERASE INHIBITORS AND THERAPEUTIC USES THEREOF UNIVERSITY OF MYSORE (IN) 2017-02-23 WO disclosed
EP-2349999-B1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIV SAARLAND (DE) 2016-01-27 EP disclosed
US-8912186-B2 Allosteric protein kinase modulators UNIVERSITAET DES SAARLANDES (DE) 2014-12-16 US disclosed
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2012-02-23 US disclosed
EP-2349999-A1 ALLOSTERIC PROTEIN KINASE MODULATORS Universität des Saarlandes (DE) 2011-08-03 EP disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO disclosed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 EP disclosed
US-3931152-A ANTITUBERCULAR AMERICAN CYANAMID COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS AURKC, AURKA, AURKB CYP3A4 4232/4885PTPN1 1145/4885MAOB 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.